Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test

Guardant Health Inc. (NASDAQ:GH) is one of the best mid cap pharma stocks to buy. On July 15, Guardant Health announced the enrollment of the first patient in the National Cancer Institute’s/NCI’s Vanguard Study. The 4-year study aims to enroll up to 24,000 participants to evaluate the feasibility of using multi-cancer detection/MCD tests in future randomized controlled trials.

Guardant’s Shield MCD test was selected for the study. The Shield MCD test was chosen for its overall performance in detecting 10 cancer types: lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver, and gastric. Data supporting its performance was presented at the 2025 American Society of Clinical Oncology/ASCO Annual Meeting in Chicago.

Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test

A radiologist studying a patient’s scan, looking for signs of a successful cancer treatment.

The Vanguard Study was initiated following review and approval by the US FDA as part of the NCI’s submission for an investigational device exemption/IDE. The Vanguard Study, conducted by the Cancer Screening Research, is enrolling individuals aged 45-75 who do not currently have cancer and have not received a cancer diagnosis in the past 5 years.

Guardant Health Inc. (NASDAQ:GH) is a precision oncology company that provides blood and tissue tests and data sets in the US and internationally.

While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.